Mark Emberton

About Mark Emberton

This author has not written his bio yet.
But we are proud to say that Mark Emberton contributed 6 entries already.

Entries by Mark Emberton

Editorial: Translating cost-utility modelling into the real world – the case of focal high-intensity focussed ultrasound and active surveillance

November 27, 2019/by Mark Emberton

Health economic modelling is always a challenge. The inputs are never quite what we want them to be. The literature that we have at our disposal suffers from the inevitable deficiencies of lack of maturity, ever diminishing relevance, and questionable applicability as practice evolves. The modelling can never quite reflect the nuances and vagaries of […]

Editorial: Dropping the GAD – just a fad?

July 24, 2019/by Mark Emberton

It is not without irony that, at the very moment that the UK’s National Institute for Health and Care Excellence (NICE) is poised to ratify the recommendation that multiparametric MRI (mpMRI) be introduced into the prostate cancer diagnostic pathway, we are seeking to significantly modify the very intervention on which they are about to provide […]

Editorial: Has tailored, tissue‐selective tumour ablation in men with prostate cancer come of age?

May 23, 2018/by Mark Emberton

There are two principal challenges that face the growing number of clinical investigators that are evaluating tissue‐preserving therapies in men with prostate cancer. The first is that every man’s prostate is different. So different and so unique are the personal attributes of a man’s prostate that it would, just like the iris or fingerprint, qualify […]

Editorial: An end to the phenomenon of ‘upgrading’ in early prostate cancer?

March 29, 2017/by Mark Emberton

The phenomenon of ‘upgrading’ in early prostate cancer is one of those unusual events that is both useful to us on the one hand and undesirable on the other; useful because the phenomenon gifts us a direct measure of the precision of our risk stratification methods for men recently diagnosed, and undesirable because the perfect […]

Editorial: Doubling our precision of risk stratification in early prostate cancer? Too good to be true?

January 13, 2016/by Mark Emberton

It is difficult to over-estimate the enormity of the revolution involved in transitioning away from an organ-based system of care in prostate cancer (prostatectomy or radiotherapy to prostate cancer of any grade, number, location or volume) to one in which the target condition is defined and verified, and then subsequently treated with a margin. Since […]

Editorial: Are men who are biopsied without prior prostate magnetic resonance imaging getting substandard care?

December 9, 2015/by Mark Emberton

The article by Borkowetz et al. [1], published in this issue, by a multi-disciplinary group from Dresden who have been offering MRI to their patients since 2012, would suggest so. In their hands, an image-guided biopsy resulted in 29 patients with Gleason scores of 7 or 8 being identified, who had been overlooked by an optimised […]

Author Archive for: Mark Emberton

About Mark Emberton

Entries by Mark Emberton